CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENTCollaboration and Supply Agreement • March 16th, 2022 • BioLineRx Ltd. • Pharmaceutical preparations • New York
This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this “Agreement”), made as of January 11, 2016 (the “Effective Date”), is by and between Merck Sharp & Dohme B.V., having a place of business at Waarderweg 39, 2031 BN Haarlem, Netherlands (“Merck”) and BioLineRx Ltd., having a place of business at Modi’in Technology Park, 2 HaMa’ayan Street, Modi’in 7177871, Israel (“BioLineRx”). Merck and BioLineRx are each referred to herein individually as a “Party” and collectively as the “Parties”.
CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENTCollaboration and Supply Agreement • June 12th, 2020 • Nugenerex Immuno-Oncology, Inc. • Pharmaceutical preparations • New York
CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (FOR NON-SMALL CELL LUNG CANCER STUDY WITH EXPANSION COHORTS IN NON-SMALL CELL LUNG CANCER AND MELANOMA)Collaboration and Supply Agreement • January 4th, 2016 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this “Agreement”), made as of March 27, 2015 (the “Effective Date”), is by and between MSD International GmbH, having a place of business at Weystrasse 20, 6000 Luzern, Switzerland (“Merck”), and Syndax Pharmaceuticals, Inc., having a place of business at 400 Totten Pond Road, Suite 110, Waltham, MA 02451 (“Syndax”). Merck and Syndax are each referred to herein individually as “Party” and collectively “Parties”.
EXHIBIT 10.66 COLLABORATION AND SUPPLY AGREEMENTCollaboration and Supply Agreement • March 15th, 2004 • Caliper Life Sciences Inc • Laboratory analytical instruments • California
Amendment No. 2 to Amended and Restated Clinical Collaboration and Supply AgreementCollaboration and Supply Agreement • May 8th, 2024 • Olema Pharmaceuticals, Inc. • Pharmaceutical preparations
Reference is hereby made to the Clinical Collaboration and Supply Agreement, dated July 22, 2020, as amended via the Amended and Restated Clinical Collaboration and Supply Agreement, dated January 13, 2022, and the Amendment No. 1 to Amended and Restated Clinical Collaboration and Supply Agreement, dated October 5, 2023 (collectively the “Agreement”), by and between Olema Pharmaceuticals, Inc., a Delaware corporation, having a place of business at 780 Brannan Street, San Francisco, CA 94103 (“Olema”), and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation, having a place of business at 181 Massachusetts Avenue, Cambridge, MA 02139 (“Novartis”).
CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (RP-2)Collaboration and Supply Agreement • June 3rd, 2020 • Replimune Group, Inc. • Biological products, (no disgnostic substances) • Delaware
This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (RP-2) (the “Agreement”) is made and entered into effective as of the date signed by the last Party to sign below (the “Effective Date”) by and between Replimune Inc., a corporation organized under the laws of Delaware, having a place of business at 18 Commerce Way, Woburn, MA 01801 (the “Recipient”) and Bristol-Myers Squibb Company, having a place of business at 345 Park Avenue, New York, NY 10154 (“BMS”). The Recipient and BMS are sometimes individually referred to in this Agreement as a “Party” and collectively as the “Parties.”
Collaboration and Supply Agreement between Marinus Pharmaceuticals, Inc. and Tenacia Biotechnology (Shanghai) Co., Ltd.Collaboration and Supply Agreement • March 9th, 2023 • Marinus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This COLLABORATION AND SUPPLY AGREEMENT is made and entered into as of November 16, 2022 (“Effective Date”) between Marinus Pharmaceuticals, Inc. (“Marinus”), a Delaware corporation with principal offices at 5 Radnor Corporate Center, Suite 500, 100 Matsonford Road, Radnor, Pennsylvania 19087 USA, and Tenacia Biotechnology (Shanghai) Co., Ltd. (“Company”), a company organized and existing under the laws of PRC, located at Room 368, Part 302, 211 North Fute Road, China (Shanghai) Pilot Free Trade Zone. Marinus and Company may be referred herein individually as a “Party” or collectively as the “Parties.”
Confidential CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (For Study PRS‐343‐PCS_09_20 and Lilly I4T-NS-I025) This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this "Agreement"), made as of August 10, 2020 (the "Effective Date"), is by and...Collaboration and Supply Agreement • November 4th, 2020 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research • New York
COLLABORATION AND SUPPLY AGREEMENT by and between RayzeBio, Inc. And Niowave, Inc.Collaboration and Supply Agreement • February 11th, 2022 • RayzeBio, Inc. • Pharmaceutical preparations • New York
This Collaboration and Supply Agreement (this “Agreement”) dated as of May 26, 2021 (the “Effective Date”), by and between RayzeBio, Inc., a Delaware corporation having a place of business at 9880 Campus Point Dr, Suite 410, San Diego, CA 92121 (“RayzeBio”), and Niowave, Inc., a Michigan corporation having a place of business at 1012 N. Walnut Street, Lansing, MI 48906, USA (“Niowave”).
AMENDMENT NO. 2 TO CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENTCollaboration and Supply Agreement • March 16th, 2022 • BioLineRx Ltd. • Pharmaceutical preparations
This Amendment No. 2 to the CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this “Amendment No. 2”), made as of the date of last signature hereunder (the “Amendment No. 2 Effective Date”), is by and between Merck Sharp & Dohme B.V. (“Merck”) and BioLineRx Ltd. (“BioLineRx”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement.
COLLABORATION AND SUPPLY AGREEMENTCollaboration and Supply Agreement • February 13th, 2009 • Dor Biopharma Inc • Pharmaceutical preparations • New Jersey
DOR BioPharma Inc., a Delaware corporation having its principal office at 850 Bear Tavern Road, Suite 201, Ewing, New Jersey 08628 (the “COMPANY”), and Enteron Pharmaceuticals, Inc., a wholly owned subsidiary of the COMPANY, (“ENTERON”, and together with the COMPANY, “DOR”), each
INDICATES CONFIDENTIAL MATERIAL OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED WITH THE SECURITIES AND EXCHANGE COMMISSION SEPARATELY WITH A REQUEST FOR CONFIDENTIAL TREATMENT. CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT by...Collaboration and Supply Agreement • October 19th, 2018 • IMMUTEP LTD • Pharmaceutical preparations • New York
This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this “Agreement”), is entered into as of March 12, 2018 (the “Effective Date”), by and between Merck Sharp & Dohme B.V., having a place of business at Waarderweg 39, 2031 BN Haarlem, Netherlands (“MSDBV”), MSD International GmbH, having a place of business at Weystrasse 20, 6000 Luzern 6, Switzerland (“MSDIG”, and, collectively with MSDBV, “Merck”), and Immutep Limited, having a place of business at Level 12, 95 Pitt Street, Sydney, NSW, Australia 2000 (“Company”). Merck and Company are each referred to herein individually as “Party” and collectively as “Parties”.
AMENDMENT TO THE COLLABORATION AND SUPPLY AGREEMENT BETWEEN SOLIGENIX, INC., ENTERON PHARMACEUTICALS, INC. AND SIGMA-TAU PHARMACEUTICALS, INC.Collaboration and Supply Agreement • July 28th, 2011 • Soligenix, Inc. • Pharmaceutical preparations
This amendment (the "Amendment") is entered into effective as of the 26th day of July, 2011 (the “Amendment Effective Date”) by and between, on the one hand, Soligenix, Inc. (formerly known as DOR BioPharma, Inc.), a Delaware corporation (“SOLIGENIX”), Enteron Pharmaceuticals, Inc., a Delaware corporation a wholly-owned subsidiary of Soligenix (“Enteron”, and together with Soligenix, the “Company”) and on the other hand, Sigma-Tau Pharmaceuticals, Inc. (“Sigma-Tau”).
CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENTCollaboration and Supply Agreement • March 28th, 2019 • BioLineRx Ltd. • Pharmaceutical preparations
This Amendment No. 2 to the CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this “Amendment No. 2”), made as of the date of last signature hereunder (the “Amendment No. 2 Effective Date”), is by and between Merck Sharp & Dohme B.V. (“Merck”) and BioLineRx Ltd. (“BioLineRx”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement.
AMENDMENT No. 1 to Clinical Trial Collaboration and Supply AgreementCollaboration and Supply Agreement • May 10th, 2021 • Aveo Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 1 to Clinical Trial Collaboration and Supply Agreement (this “Amendment No. 1") is effective as of the date signed by the last party to sign below (the “Amendment No. 1 Effective Date”) and is made and entered into by and among Aveo Pharmaceuticals, Inc., having a place of business at 30 Winter Street, Boston, MA 02108 (“Recipient”) and Bristol-Myers Squibb Company, having a place of business at Route 206 & Province Line Road, Princeton, New Jersey 08543-4000, New York, New York 10154 (“BMS").
Clinical Trial Collaboration and Supply Agreement by and among MSD International GmbH, MSD International Business GmbH, and Collaborator (as defined below) Clinical Trial Collaboration and Supply Agreement - Information SheetCollaboration and Supply Agreement • December 6th, 2021 • IO Biotech, Inc. • Pharmaceutical preparations • New York
This Clinical Trial Collaboration and Supply Agreement is entered into as of the Effective Date, by and among MSD International GmbH (“MSDIG”), MSD International Business GmbH (“MSDIB” and, collectively with MSDIG, “MSD”), each having a place of business at [***], and Collaborator (as defined below), having a place of business at the Collaborator Address (as defined below). MSD and Collaborator are each referred to herein individually as a “Party” and collectively as the “Parties”.
COLLABORATION AND SUPPLY AGREEMENTCollaboration and Supply Agreement • March 9th, 2021 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
This Collaboration and Supply Agreement (“Agreement”) is made and entered into as of May 15, 2018 (the “Effective Date”) by and between Eiger BioPharmaceuticals, Inc., a Delaware corporation having a place of business at 350 Cambridge Avenue, Suite 350, Palo Alto, CA 94306 (“Eiger”), and The Progeria Research Foundation, Inc., a 501(c)(3) not-for-profit organization currently located at 200 Lake St., Peabody MA 01960 (“PRF”). Eiger and PRF are individually referred to as a “Party” and collectively referred to as the “Parties.”
Collaboration AND Supply AgreementCollaboration and Supply Agreement • August 10th, 2018 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
This Collaboration and Supply Agreement (“Agreement”) is made and entered into as of May 15, 2018 (the “Effective Date”) by and between Eiger BioPharmaceuticals, Inc., a Delaware corporation having a place of business at 350 Cambridge Avenue, Suite 350, Palo Alto, CA 94306 (“Eiger”), and The Progeria Research Foundation, Inc., a 501(c)(3) not-for-profit organization currently located at 200 Lake St., Peabody MA 01960 (“PRF”). Eiger and PRF are individually referred to as a “Party” and collectively referred to as the “Parties.”
AMENDMENT NO. 2 TO THE COLLABORATION AND SUPPLY AGREEMENT BETWEEN SOLIGENIX, INC., ENTERON PHARMACEUTICALS, INC. and SIGMA-TAU PHARMACEUTICALS, INC.Collaboration and Supply Agreement • December 27th, 2012 • Soligenix, Inc. • Pharmaceutical preparations
This Amendment no.2 ("Amendment") is entered into effective as of the 20th day of December, 2012 (the “Amendment Effective Date”) by and between, on the one hand, Soligenix, Inc. (formerly known as DOR BioPharma, Inc.), a Delaware corporation (“SOLIGENIX”), Enteron Pharmaceuticals, Inc., a Delaware corporation a wholly-owned subsidiary of Soligenix (“Enteron”, and together with Soligenix, the “Company”) and on the other hand, Sigma-Tau Pharmaceuticals, Inc. (“Sigma-Tau”).
Amendment No. 1 to Amended and Restated Clinical Collaboration and Supply AgreementCollaboration and Supply Agreement • October 10th, 2023 • Olema Pharmaceuticals, Inc. • Pharmaceutical preparations
Reference is hereby made to the Clinical Collaboration and Supply Agreement, dated July 22, 2020, as amended via the Amended and Restated Clinical Collaboration and Supply Agreement, dated January 13, 2022 (collectively the “Agreement”), by and between Olema Pharmaceuticals, Inc., a Delaware corporation, having a place of business at 780 Brannan Street, San Francisco, CA 94103 (“Olema”), and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation, having a place of business at 181 Massachusetts Avenue, Cambridge, MA 02139 (“Novartis”).
Amendment No. 1 to the Collaboration and Supply AgreementCollaboration and Supply Agreement • August 6th, 2020 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 (“Amendment”) is effective as of June 15, 2020 (the “Amendment Effective Date”) by and between Eiger BioPharmaceuticals, Inc., a Delaware corporation currently located at 2155 Park Boulevard, Palo Alto, CA 94306 (“Eiger”), and The Progeria Research Foundation, Inc., a 501(c)(3) not-for-profit organization currently located at 200 Lake St., Peabody MA 01960 (“PRF”) and amends the Collaboration and Supply Agreement, dated May 15, 2018, by and between Eiger and PRF (“Agreement”). Certain capitalized terms used herein but not expressly defined in this Amendment will have the meanings given in the Agreement.
CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. FIRST (1st) AMENDMENT TO CLINICAL TRIAL COLLABORATION AND...Collaboration and Supply Agreement • October 27th, 2021 • SpringWorks Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Amendment No. 1 to that certain Clinical Trial Collaboration and Supply Agreement (the “Agreement”), dated as of June 25, 2019, between GlaxoSmithKline LLC (“GSK”) and SpringWorks Therapeutics, Inc. (“SpringWorks”) is dated as of October 22, 2021 (the “Amendment Effective Date”).
